Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
McKinsey
Colorcon
Moodys
Johnson and Johnson

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ganetespib

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Ganetespib?

Ganetespib is an investigational drug.

There have been 31 clinical trials for Ganetespib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Breast Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Synta Pharmaceuticals Corp., Dana-Farber Cancer Institute, and Emory University.

There are twenty US patents protecting this investigational drug and three hundred and thirty-five international patents.

Recent Clinical Trials for Ganetespib
TitleSponsorPhase
European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerEuropean CommissionPhase 2
European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerUniversitaire Ziekenhuizen LeuvenPhase 2
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast CancerUniversity of ChicagoN/A

See all Ganetespib clinical trials

Clinical Trial Summary for Ganetespib

Top disease conditions for Ganetespib
Top clinical trial sponsors for Ganetespib

See all Ganetespib clinical trials

US Patents for Ganetespib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ganetespib   Start Trial Resorcinol derivative as HSP90 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (Lianyungang, CN)   Start Trial
Ganetespib   Start Trial Pyrimidine-diamine dual HSP90/TRAP1 inhibitors Calasia Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Ganetespib   Start Trial Triazole compounds that modulate Hsp90 activity Synta Pharmaceuticals Corp. (Lexington, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Boehringer Ingelheim
Mallinckrodt
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.